An interview with the patient was performed 72 hours after treatment to detect a possible relapse of headache. Results: Thirty-one migraine status patients, comprising 28 women and 3 men at a mean±SD age of 33.355±12.373 SD, were investigated. Differences in the selleck chemical Palbociclib therapeutic effects of IVVP (Orifil) and IVDEX on pain score were not significant between the two groups (t=0.933, df=29; P=0.358). Relapse of headache occurred in 68.42% of the IVVP (Orifil) group and 66.67% of the IVDEX group.
Distribution of relapse was not significantly different between the two therapeutic groups of patients (P=0.870). Conclusion: IVVP (Orifil) was similar in efficacy to IVDEX as abortive therapy in Inhibitors,research,lifescience,medical patients with migraine status. IVVP (Orifil) appears to offer Inhibitors,research,lifescience,medical a safe and well-tolerated abortive treatment. Trial Registration Number: IRCT13891146234N2 Key Words: Valproic acid, Dexamethasone, Migraine disorders Introduction New Triptan drugs such as Almotriptan,1 and Lasmiditan,2 and other new drugs such as Telcageptant,3 and Tonabersat,4 have been developed for acute migraine management. Meanwhile, the treatment of migraine status remains a therapeutic challenge in some cases. There is an ongoing search for new treatment approaches
for patients suffering from migraine and other headaches that are refractory to the usual abortive therapies.5 Oral selleck chemicals Valproate is utilized widely as a preventive drug for Inhibitors,research,lifescience,medical migraine and for chronic daily headaches of migraine.1,2 Intravenous Valproate (IVVP) as abortive therapy has been administered in different doses Inhibitors,research,lifescience,medical for the management
of migraine status in some studies.6,7 Many patients suffer prolonged, moderate, or severe migraines, and IVVP offers another weapon against these prolonged migraines. IVVP (Orifil) was studied for the treatment of migraine Inhibitors,research,lifescience,medical attacks in Israel,8 where the loading dose of IVVP (Orifil) was 900-1200 mg and the average time to best response for headache severity was 50 minutes. In addition, there was a significant reduction in pain severity (P<0.0001), and there were no serious adverse events. The ease of IVVP administration and absence of side effects are also important considerations; be that as it may, future double-blind studies will help clarify the situation.9 To review the literature regarding the use of intravenous valproic acid in aborting an acute migraine attack, a Medline (1967-June 2007) and bibliographic search Cilengitide of the English language literature was conducted using the search terms “valproic acid” and “migraine disorders”.10 All articles identified through the search were included.10 The use of intravenous valproic acid has been studied as a possible treatment for acute migraine.10 Available studies are small, mostly open-label and non-placebo-controlled, and used variable doses.10 Valproic acid has not been shown to be superior to comparator drugs.